ESG risk score 38.1
Environmental score -
Social score -
Governance score -
ESG risk category High
Negligible Low Med High Severe
0-10 10-20 20-30 30-40 40+
Outlook Therapeutics Inc.
000.00
0.00 / 0.00%
00:00:00
52 week range
0000.00 000.00
Symbol OTLK:xnas
Currency USD
NASDAQ (Small cap)
Open Closed
15 minutes delayed
Data provided by 
This information is not currently available for this instrument. Refresh the page or try again later.
Ready to start investing?
Trade stocks with a regulated broker present in Singapore since 2006.
Chart
This information is not currently available for this instrument. Refresh the page or try again later.
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
This information is not currently available for this instrument. Refresh the page or try again later.
Returns
Year to date (YTD) -81.96%
1 year -81.37%
3 years -73.11%
Data provided by 
Key stats
Price/earnings (LTM) -
Dividend yield (LTM) -
EPS (LTM) -1.71
Volatility (30 days) 141.42%
Data provided by
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Data provided by 
/ 
/ Financials
Q1 Q2 Q3 Q4
Income statement
Revenue XXXXXXX XXXXXXX XXXXXXX XXXXXXX
EBITDA XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Net income XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Balance sheet
Total assets XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Total debt XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Ratios
Price/sales XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Earnings per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Dividend per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Return on equity XXXXXXX XXXXXXX XXXXXXX XXXXXXX
About Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Sector Healthcare
Industry -
Market cap 0.03164674bn
Data provided by /
/ Frequently asked questions
You need to open and fund a Saxo account to buy Outlook Therapeutics Inc. stock. Once the account is approved, you can login to the platform (SaxoInvestor or SaxoTrader), search for Outlook Therapeutics Inc. (by name) or ‘APPL’ (by ticker), choose the number of shares you wish to buy, and place your order.
The ticker symbol for Outlook Therapeutics Inc. is OTLK:xnas. You can use this code to find the stock in our platforms and track its price and performance.
Outlook Therapeutics Inc. has its primary listing on NASDAQ (Small cap). You can trade Outlook Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Outlook Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy Outlook Therapeutics Inc. stock directly and include it as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Outlook Therapeutics Inc. or others.